Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27733401 | 0.85 | SMN1; SMN2 (0.40) | MAOBALDH1A1AOC3MEN1KMT2A | |
| SCHEMBL12926333 | 0.82 | SMN1; SMN2 (0.36) | MAOBALDH1A1AOC3MEN1KMT2A | |
| SCHEMBL3589633 | 0.82 | NQO1 (0.50) | MAOBLTA4HMAPT | |
| SCHEMBL19228661 | 0.82 | LMNA (0.47) | MAOBALDH1A1AOC3CHRNB2CHRNB4 | |
| SCHEMBL12409059 | 0.82 | NOS1 (0.49) | MAOBALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2129443 | 0.81 | SMN1; SMN2 (0.53) | MAOBALDH1A1AOC3MEN1KMT2A | |
| SCHEMBL12926334 | 0.81 | MEN1 (0.50) | ALDH1A1MEN1KMT2ALMNAMAPT | |
| SCHEMBL8237725 | 0.78 | NQO1 (0.64) | MAOBALDH1A1AOC3CHRNB2CHRNB4 | |
| SCHEMBL1040476 | 0.77 | L3MBTL1 (0.55) | MAOBALDH1A1AOC3KMT2ALMNA | |
| SCHEMBL14930472 | 0.77 | KDM4E (0.46) | MAOBCHRNB2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116621729-B | Perfluoro phenyl substituted salicylaldimine nickel complex, preparation method and application thereof | 华东理工大学 | 2025-06-24 | — | — | CN | disclosed |
| CN-116621729-A | Perfluoro phenyl substituted salicylaldimine nickel complex, preparation method and application thereof | 华东理工大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-105492075-A | Inhibitors of viral replication, their process of preparation and their therapeutical uses | MUTABILIS SA | 2016-04-13 | — | — | CN | disclosed |
| CN-100447149-C | COMT inhibitors | HOFFMANN LA ROCHE (CH) | 2008-12-31 | — | — | CN | disclosed |
| US-7319101-B2 | COMT inhibitors for the treatment of depression and impaired cognition | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1790644-A1 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2007-05-30 | — | — | EP | disclosed |
| US-7217734-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217734-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1697394-B1 | COMT INHIBITORS | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | EP | disclosed |
| CN-1886416-A | COMT inhibitors | HOFFMANN LA ROCHE (CH) | 2006-12-27 | — | — | CN | disclosed |
| EP-1697394-A2 | COMT INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058228-A2 | COMT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050137162-A1 | New COMT inhibitors for the treatment of depression and impaired cognition | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-23 | — | — | US | disclosed |
| US-20040087436-A1 | Novel polymerisation catalysts | BP CHEMICALS LIMITED (GB) | 2004-05-06 | — | — | US | disclosed |
| US-20040033899-A1 | 5[(pyrazol-4-yl)carbonyl]benzazolone as herbicide | BASF AKTIENGESELLSCHAFT (DE) | 2004-02-19 | — | — | US | disclosed |
| US-5587392-A | THERAPY FOR ESTROGEN DEPENDENT DISEASES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5521202-A | ANTIDIABETIC AGENTS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-05-28 | — | — | US | disclosed |
| EP-0684235-A1 | Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033899-A1 | 5[(pyrazol-4-yl)carbonyl]benzazolone as herbicide | CBR3, DDT, CYP1B1 | MAOB 2968/4885ALDH1A1 121/4885AOC3 1572/4885 |
| US-20040087436-A1 | Novel polymerisation catalysts | SCO2, PDS5A, MT-CO3 | MAOB 1697/4885ALDH1A1 3838/4885AOC3 956/4885 |
| US-20050137162-A1 | New COMT inhibitors for the treatment of depression and impaired cognition | COMT, MAOB, TPH1 | MAOB 2/4885ALDH1A1 46/4885AOC3 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.